AKIR001 radiopharmaceutical shows no dose-limiting toxicities in eight patients

The Phase I trial of the radiopharmaceutical 177Lu-AKIR001 targeting CD44v6-positive solid tumors reported no dose-limiting toxicities in eight patients, with treatment-related adverse events limited to grade 1-2. Quantitative imaging demonstrated selective tumor retention and clearance from healthy tissues, and immunohistochemistry may be used to select patients who would benefit from treatment.

This Wire brief sits within Fusion42's coverage of Biotech.